Showing 4061-4070 of 4926 results for "".
- EWG: Two-Thirds of Sunscreen Products Offer Poor Protection or Have Worrisome Ingredientshttps://practicaldermatology.com/news/ewg-two-thirds-of-sunscreen-products-offer-poor-protection-or-have-worrisome-ingredients/2457756/The Environmental Working Group (EWG) released its 12th annual Guide to Sunscreens, rating the safety and efficacy of more than 1,000 sunscreens, moisturizers and lip balms that advertise sun protection, and found
- Greater Skin Cancer Risk Seen in U.S. Military Personnelhttps://practicaldermatology.com/news/greater-skin-cancer-risk-seen-in-us-military-personnel/2457762/U.S. military personnel are more likely to develop skin cancer than the general population, according to a review of nine published studies in the Journal of the American Academy of Dermatology (JADD). The f
- FDA Frowns on Evolus' Botox Rivalhttps://practicaldermatology.com/news/fda-frowns-on-evolus-botox-rival/2457763/The U.S Food and Drug Administration did not approve DWP-450, Evolus Inc's rival product to Allergan Plc's Botox, due to chemistry and manufacturing issues. As a result, the company pushed its estimate for the launch of the drug to the spring of next year. Read more
- Aclaris to Support Symposium on JAK Inhibitors at the International Investigative Dermatology 2018 Meetinghttps://practicaldermatology.com/news/aclaris-to-support-symposium-on-jak-inhibitors-at-the-international-investigative-dermatology-2018-meeting/2457767/Aclaris Therapeutics, Inc. has provided an unrestricted educational grant for the symposium on Janus Kinase (JAK) inhibitors at the International Investigative Dermatology (IID) 2018 Meeting in Orlando, FL. The symposium, titled “JAKs Be Nimble: New Applications of JAK Inhibitors in Dermato
- And the Winner Is...Consumer Reports Releases Annual Sunscreen Ratingshttps://practicaldermatology.com/news/consumer-reports-releases-annual-sunscreen-ratings/2457769/Drumroll please… The annual Consumer Reports sunscreen ratings are in. Just one product, La Roche-Posay Anthelios 60 Melt-In Sunscreen Milk, came
- Sinclair Will Market and Distribute Silhouette InstaLift in UShttps://practicaldermatology.com/news/sinclair-to-market-and-distribute-silhouette-instalift-in-the-us/2457773/Silhouette Lift, Inc.. a Sinclair Pharma Company, is now handling all of the commercial aspects of the Silhouette InstaLift portfolio of resorbable skin lifting sutures including sales and marketing, and order fulfillment. They are also relaunching
- Study Seeks to Harness the Power of Probiotics to Treat Eczemahttps://practicaldermatology.com/news/study-seeks-to-harness-the-power-of-probiotics-to-treat-eczema/2457778/A new clinical trial is investigating whether beneficial bacteria can help treat eczema by restoring the natural microbial balance of healthy skin. "There are over 1,000 species of bacteria that all live in balance on healthy skin, some that even produce natural antibiotics. However,
- Bath Emollients Don't Add Much to Standard Eczema Carehttps://practicaldermatology.com/news/bath-emollients-dont-add-much-to-standard-eczema-care/2457784/Emollient bath additives provide no meaningful benefit when used in addition to standard eczema care in children, according to research in the BMJ. UK researchers, led by Miriam Santer, MBBChir
- FDA Agrees to Priority Review of Cemiplimab for Advanced Squamous Cell Carcinomahttps://practicaldermatology.com/news/fda-agrees-to-priority-review-of-cemiplimab-for-advanced-squamous-cell-carcinoma/2457785/The FDA has accepted the Biologics License Application (BLA) for cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC w
- FDA Approves Tafinlar + Mekinist for Adjuvant Treatment of BRAF V600-Mutant Melanomahttps://practicaldermatology.com/news/fda-approves-tafinlar-mekinist-for-adjuvant-treatment-of-braf-v600-mutant-melanoma/2457786/The FDA has approved Novartis' Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. The FDA